Article (Scientific journals)
In FUS[1−359]‐tg mice O,S-dibenzoyl thiamine reduces muscle atrophy, decreases glycogen synthase kinase 3 beta, and normalizes the metabolome
Probert, Fay; Gorlova, Anna; Deikin, Alexei et al.
2022In Biomedicine and Pharmacotherapy, 156, p. 113986
Peer Reviewed verified by ORBi
 

Files


Full Text
Probert et a._2022.pdf
Publisher postprint (3.04 MB) Creative Commons License - Attribution
Download
Annexes
1-s2.0-S0753332222013750-mmc1.docx
(79.97 kB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Amyotrophic lateral sclerosis; Fused in Sarcoma protein; Thiamine; Neuroinflammation; Cytokine; Lactate
Abstract :
[en] Mutations in the gene encoding the RNA/DNA-binding protein Fused in Sarcoma (FUS) have been detected in familial amyotrophic lateral sclerosis (ALS) patients. FUS has been found to be a critical component of the oxidative damage repair complex that might explain its role in neurodegeneration. Here, we examined what impact antioxidant treatment with thiamine (vitamine B1), or its more bioavailable derivative O,S- dibenzoylthiamine (DBT), would have on the hallmarks of pathology in the FUS[1− 359]-transgenic mouse model of ALS. From 8-weeks old, in the pre-symptomatic phase of disease, animals received either thiamine, DBT (200 mg/kg/day), or vehicle for 6 weeks. We examined physiological, behavioral, molecular and histological outcomes, as well as the serum metabolome using nuclear magnetic resonance (NMR). The DBT-treated mice displayed improvements in physiological outcomes, motor function and muscle atrophy compared to vehicle, and the treatment normalized levels of brain glycogen synthase kinase-3β (GSK-3β), GSK-3β mRNA and IL-1β mRNA in the spinal cord. Analysis of the metabolome revealed an increase in the levels of choline and lactate in the vehicle-treated FUS mutants alone, which is also elevated in the cerebrospinal fluid of ALS patients, and reduced glucose and lipoprotein concentrations in the FUS[1− 359]-tg mice, which were not the case in the DBT- treated mutants. The administration of thiamine had little impact on the outcome measures, but it did normalize circulating HDL levels. Thus, our study shows that DBT therapy in FUS mutants is more effective than thiamine and highlights how metabolomics may be used to evaluate therapy in this model.
Research center :
GIGA Neurosciences-Neurophysiology - ULiège
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Probert, Fay
Gorlova, Anna
Deikin, Alexei
Bettendorff, Lucien  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie humaine et pathologique
Veniaminova, Ekaterina
Nedorubov, Andrey
Chaprov, Kirill D.
Ivanova, Tamara A.
Anthony, Daniel C.
Strekalova, Tatyana
Language :
English
Title :
In FUS[1−359]‐tg mice O,S-dibenzoyl thiamine reduces muscle atrophy, decreases glycogen synthase kinase 3 beta, and normalizes the metabolome
Publication date :
November 2022
Journal title :
Biomedicine and Pharmacotherapy
ISSN :
0753-3322
eISSN :
1950-6007
Publisher :
Elsevier BV
Volume :
156
Pages :
113986
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
PhytoAPP EU; HORIZON 2020
Funders :
EU - European Union [BE]
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 08 November 2022

Statistics


Number of views
35 (2 by ULiège)
Number of downloads
43 (0 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi